ERBB2 and breast carcinoma: Multiple phase II/III trials have confirmed that in terms of progression‐free survival, patients with endocrine‐resistant, HR‐positive/HER2‐negative advanced breast cancer can benefit from combination therapy of everolimus plus endocrine therapy (such as letrozole, exemestane, or fulvestrant) [17, 18, 19, 20, 21].